• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Delcath Systems Inc.

Delcath approves massive reverse split

April 9, 2018 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) said today that shareholders approved a bid to increase the company’s authorized shares of common stock from 500,000,000 to 1,000,000,000. The New York-based oncology group also voted to effect a reverse stock split of Delcath’s common stock at a range of 1-for-100 to 1-for-500. The board of directors have until April 6, 2019 […]

Filed Under: Drug-Device Combinations, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath inks supply deal with Tillomed Laboratories in Europe

March 7, 2018 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) said today that it inked a commercial supply deal with Tillomed Laboratories in Europe. According to the deal, Tillomed Labs is slated to provide Delcath with melphalan – the drug used in Delcath’s hepatic Chemosat delivery system. In Europe, the drug-device combo is approved to treat liver cancer. Get the full story at […]

Filed Under: Drug-Device Combinations, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath closes $5m offering

February 12, 2018 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) has closed a $5 million offering of 212,000 shares of common stock, warrants to buy 38,000,000 shares of common stock and warrants to buy an aggregate of 500,000 shares of common stock. The New York-based company priced the offering at 2¢ per unit. Each unit was composed of one share of common stock […]

Filed Under: Drug-Device Combinations, Funding Roundup, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath touts 500th commercial Chemosat treatment in Europe

February 2, 2018 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system. The drug-device combo has been available in certain European markets since 2012. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug-Device Combinations, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Shares in Delcath fall after losses grow in Q3

November 16, 2017 By Sarah Faulkner

Shares in Delcath Systems (NSDQ:DCTHD) crashed today after the company posted its third quarter results, revealing that the company’s net losses have grown dramatically quarter-over-quarter. The N.Y.-based company posted a net loss of -$12.6 million on sales of $684,000 for the 3 months ended Sept. 30, for sales growth of 57% compared with the same period last year. […]

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath plans for 1-for-350 reverse split

November 3, 2017 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) said today that it is preparing for a 1-for-350 reverse stock split, which is set to take effect on Nov. 6. According to the terms of the reverse split, Delcath’s common stock will trade under a new symbol – DCTHD – for twenty days and then revert back to its old symbol, DCTH. […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath deal with investors raises $500k, clears path for reverse split

September 22, 2017 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) and a group of investors made an end run around the company’s shareholders with a deal that paves the way for the reverse split that stockowners have twice shot down. “Together with our Board of Directors, we are taking these actions in the best interests of all shareholders. Regaining access to equity capital will […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Wall Street Beat Tagged With: Delcath Systems Inc.

CIRSE 2017 Round-up: Delcath touts second-gen hemofiltration system in percutaneous hepatic perfusion

September 19, 2017 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) touted data today from a study of its second-generation hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan hydrochloride. The New York-based company presented the results from its study at the Cardiology and Interventional Radiology of Europe annual meeting in Copenhagen, Denmark. The investigational product, an injectable melphalan hydrochloride for use with […]

Filed Under: Clinical Trials, Drug-Device Combinations, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath readies for reverse stock split

August 28, 2017 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) said today that it inked a deal to extinguish its 2016 convertible notes with the unnamed holder of the majority of the notes. But the agreement is contingent upon the company effecting a reverse stock split – a move that shareholders voted down in June. The company’s board urged shareholders to this time […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath raises $2m in Series B stock sale

July 6, 2017 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) has raised $2 million after selling 2,360 shares of Series B preferred stock at $1,000 per share to unnamed institutional investors, according to a regulatory filing. The company wrote that it plans to use the proceeds for general corporate purposes. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug-Device Combinations, Funding Roundup, Oncology, Pharmaceutical, Vascular, Wall Street Beat Tagged With: Delcath Systems Inc.

Teleflex CEO Smith to step down | Personnel Moves | March 1, 2017

March 1, 2017 By Brad Perriello

Teleflex (NYSE:TFX) said this month that CEO Benson Smith will retire from the corner office by the end of this calendar year. Smith will continue to serve as the company’s chairman of the board. Liam Kelly, president & chief operating officer, was tapped to succeed Smith as CEO for the Wayne, Pa.-based company. “I want to […]

Filed Under: Business/Financial News Tagged With: Active Implants, Delcath Systems Inc., Glaukos, medical-metrics, Medizone, nda-partners, Novo Nordisk, Personnel Moves, SANUWAVE Health Inc., Teleflex, veracyte

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 9
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS